Figure 2 .

Proteomics stratifies SCLC into subtypes that correlate with clinical outcomes

A. NMF clustering yielded three subgroups in SCLC in the discovery cohort. B. The three subtypes based on proteomic profiling were associated with different clinical outcomes. C. The three proteomic subtypes exhibited different responses to chemotherapy. D. The predictive classifier model showing the prognosis trend similar to the discovery cohort. In the validation cohort, biopsy samples were obtained from the First Affiliated Hospital of Henan University, China. P values were determined by log-rank test (*, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., not significant). NMF, non-negative matrix factorization.